FDA to Use GVKBio’s Biomarker DB in Voluntary Exploratory Data Program | GenomeWeb
NEW YORK (GenomeWeb News) - GVK Biosciences today said it has inked an agreement that will give the US Food and Drug Administration access to the company’s Clinical Biomarker Database.
 
Under the agreement, the FDA will use the database as part of its Voluntary Exploratory Data Submission Program and in internal research projects.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.